Matinas BioPharma Holdings, Inc. (MTNB)
USD 0.59
(-2.25%)
USD 0.59
(-2.25%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.55 Million USD | -13.77% |
| 2022 | 4.12 Million USD | -12.3% |
| 2021 | 4.7 Million USD | 25.4% |
| 2020 | 3.75 Million USD | -11.35% |
| 2019 | 4.23 Million USD | 982.55% |
| 2018 | 390.74 Thousand USD | 47.51% |
| 2017 | 264.89 Thousand USD | 83.41% |
| 2016 | 144.42 Thousand USD | 1182.55% |
| 2015 | 11.26 Thousand USD | -81.12% |
| 2014 | 59.65 Thousand USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 3.39 Million USD | -4.42% |
| 2024 Q2 | 3.24 Million USD | -4.65% |
| 2023 Q4 | 3.55 Million USD | -4.1% |
| 2023 Q1 | 3.98 Million USD | -3.27% |
| 2023 FY | 3.55 Million USD | -13.77% |
| 2023 Q2 | 3.85 Million USD | -3.38% |
| 2023 Q3 | 3.7 Million USD | -3.79% |
| 2022 FY | 4.12 Million USD | -12.3% |
| 2022 Q3 | 4.23 Million USD | -4.56% |
| 2022 Q2 | 4.43 Million USD | -2.95% |
| 2022 Q4 | 4.12 Million USD | -2.55% |
| 2022 Q1 | 4.56 Million USD | -2.84% |
| 2021 FY | 4.7 Million USD | 25.4% |
| 2021 Q1 | 3.62 Million USD | -3.31% |
| 2021 Q2 | 3.51 Million USD | -3.11% |
| 2021 Q4 | 4.7 Million USD | -2.71% |
| 2021 Q3 | 4.83 Million USD | 37.58% |
| 2020 Q3 | 3.87 Million USD | -3.0% |
| 2020 FY | 3.75 Million USD | -11.35% |
| 2020 Q1 | 4.11 Million USD | -2.84% |
| 2020 Q2 | 3.99 Million USD | -2.88% |
| 2020 Q4 | 3.75 Million USD | -3.14% |
| 2019 Q3 | 4.34 Million USD | -2.52% |
| 2019 Q4 | 4.23 Million USD | -2.66% |
| 2019 FY | 4.23 Million USD | 982.55% |
| 2019 Q1 | 4.64 Million USD | 1088.94% |
| 2019 Q2 | 4.45 Million USD | -4.04% |
| 2018 Q1 | 210.29 Thousand USD | -20.61% |
| 2018 Q4 | 390.74 Thousand USD | -25.67% |
| 2018 FY | 390.74 Thousand USD | 47.51% |
| 2018 Q2 | 155.69 Thousand USD | -25.96% |
| 2018 Q3 | 525.66 Thousand USD | 237.62% |
| 2017 Q2 | 70.11 Thousand USD | -1.51% |
| 2017 FY | 264.89 Thousand USD | 83.41% |
| 2017 Q4 | 264.89 Thousand USD | -27.4% |
| 2017 Q3 | 364.84 Thousand USD | 420.36% |
| 2017 Q1 | 71.18 Thousand USD | -50.71% |
| 2016 Q2 | 30.29 Thousand USD | 0.0% |
| 2016 Q4 | 144.42 Thousand USD | -33.63% |
| 2016 FY | 144.42 Thousand USD | 1182.55% |
| 2016 Q3 | 217.62 Thousand USD | 618.29% |
| 2016 Q1 | - USD | -100.0% |
| 2015 FY | 11.26 Thousand USD | -81.12% |
| 2015 Q3 | 32.45 Thousand USD | -25.53% |
| 2015 Q2 | 43.58 Thousand USD | -20.24% |
| 2015 Q1 | 54.63 Thousand USD | -8.41% |
| 2015 Q4 | 11.26 Thousand USD | -65.3% |
| 2014 Q1 | 88.17 Thousand USD | 0.0% |
| 2014 FY | 59.65 Thousand USD | 0.0% |
| 2014 Q4 | 59.65 Thousand USD | -10.35% |
| 2014 Q3 | 66.54 Thousand USD | -14.02% |
| 2014 Q2 | 77.39 Thousand USD | -12.23% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 495 Thousand USD | -618.384% |
| Ampio Pharmaceuticals, Inc. | 274 Thousand USD | -1197.81% |
| Armata Pharmaceuticals, Inc. | 120.37 Million USD | 97.046% |
| Actinium Pharmaceuticals, Inc. | 2.11 Million USD | -68.292% |
| Azitra, Inc. | 885.94 Thousand USD | -301.378% |
| Can-Fite BioPharma Ltd. | 39.99 Thousand USD | -8790.222% |
| Chromocell Therapeutics Corporation | 1.26 Million USD | -180.29% |
| Calidi Biotherapeutics, Inc. | 7.23 Million USD | 50.857% |
| CEL-SCI Corporation | 13.57 Million USD | 73.799% |
| iBio, Inc. | 4.46 Million USD | 20.269% |
| Lineage Cell Therapeutics, Inc. | 2.95 Million USD | -20.461% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Navidea Biopharmaceuticals, Inc. | 2.43 Million USD | -46.079% |
| NovaBay Pharmaceuticals, Inc. | 2.74 Million USD | -29.781% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | 312.7 Thousand USD | -1037.181% |
| BiomX Inc. | 15.09 Million USD | 76.438% |
| BiomX Inc. | 15.09 Million USD | 76.438% |
| Protalix BioTherapeutics, Inc. | 26.28 Million USD | 86.469% |
| Palatin Technologies, Inc. | 590.33 Thousand USD | -502.367% |
| Scorpius Holdings, Inc. | 14.04 Million USD | 74.676% |
| Theriva Biologics, Inc. | 2.15 Million USD | -65.088% |